NEW YORK, Aug. 25, 2017 /PRNewswire/ -- Bernstein Liebhard LLP today announced that only 10 days remain to file a motion for lead plaintiff in a securities class action pending in the United States District Court for the District of New Jersey on behalf of a class (the "Class") consisting of all persons or entities who purchased the securities of Ocular Therapeutix, Inc. ("Ocular" or the "Company") (NASDAQ: OCUL) during the period between March 10, 2016 and July 11, 2017, inclusive (the "Class Period"). The complaint alleges that Defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.
The complaint alleges that, throughout the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) Ocular failed to adequately address issues identified in the First Form 483; (ii) Ocular's re-submitted NDA would not be approved by the July 19, 2017 PDUFA date because the Company could not timely and adequately address the FDA-identified manufacturing and control issues; (iii) Ocular's continued manufacturing issues imperil the approval of DEXTENZA; and (iv) as a result, Defendants' public statements were materially false and misleading at all relevant times.
Plaintiffs seek to recover damages on behalf of all Class members who invested in Ocular securities during the Class Period. If you invested in Ocular securities as described above, and lost money on the transactions, you may wish to join in this action to serve as lead plaintiff. In order to do so, you must meet certain requirements set forth in the applicable law and file appropriate papers no later than September 5, 2017.
A "lead plaintiff" is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Under certain circumstances, one or more class members may together serve as lead plaintiff. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. You may retain Bernstein Liebhard LLP, or other counsel of your choice, to serve as your counsel in this action.
If you are interested in discussing your rights as an Ocular investor and/or have information relating to the matter, please contact Joseph R. Seidman, Jr. at (877) 779-1414 or email@example.com.
Bernstein Liebhard LLP has pursued hundreds of securities, consumer and shareholder rights cases and recovered over $3.5 billion for its clients. The Firm has been named to the National Law Journal's "Plaintiffs' Hot List" thirteen times.
You can obtain a copy of the complaint from the clerk of the court for the United States District Court for the District of New Jersey.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2017 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
View original content:http://www.prnewswire.com/news-releases/bernstein-liebhard-llp-announces-that-only-10-days-remain-to-file-a-motion-for-lead-plaintiff-in-a-class-action-filed-against-ocular-therapeutix-inc-300509725.html
SOURCE Bernstein Liebhard LLP